brimonidine hemipamoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: brimonidine hemipamoate
• 英文别名: 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine;4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid
• 化学式: C₁₁H₁₀BrN₅*0C₂₃H₁₆O₆
• 分子量: 486.326
• InChiKey: AIJKFCBZCKCUNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.15
• 重原子数：
  46
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  177
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  溴莫尼定 、 帕莫酸 以 乙醇 、 二甲基亚砜 为溶剂， 反应 0.5h， 生成 brimonidine hemipamoate
  参考文献：
  名称：

  Polymorphs of Brimonidine Pamoate

  摘要：

  一种布里莫尼定帕莫酸盐多晶体表现出本文披露的特征。该多晶体包含在一种用于治疗或控制眼内压升高或神经保护神经组织成分以防止这些成分逐渐退化的组合物、装置或植入物中。特别是，这样的组合物、装置或植入物可用于为视神经系统的细胞和成分提供神经保护。

  公开号：

  US20100125077A1

文献信息

• Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
  申请人：McIntire Gregory L.

  公开号：US20080293728A1

  公开（公告）日：2008-11-27

  A complex comprises at least an α 2 -adrenergic receptor agonist and a compound that provides an opposite charge to a charge on the α 2 -adrenergic receptor agonist, wherein the complex is charge neutral as a whole and has a solubility in a range from about 0.3 μg/ml to about 2.5 mg/ml in water at pH of about 7 and temperature of about 25° C. The complex is included in a composition, device, or implant for use in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system.

  一个复合物至少包含一个α2肾上腺素受体激动剂和一个提供与α2肾上腺素受体激动剂相反电荷的化合物，其中整体上复合物是电中性的，在pH约为7和温度约为25°C的水中的溶解度在约0.3μg/ml至约2.5mg/ml的范围内。该复合物包含在一种组合物、设备或植入物中，用于在神经组织的组分中进行神经保护，以防止这些组分的逐渐退化。特别是，这样的组合物、设备或植入物可用于为视神经系统的细胞和组分提供神经保护。
• Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma
  申请人：McIntire Gregory L.

  公开号：US20110183946A1

  公开（公告）日：2011-07-28

  A complex comprises at least an α 2 -adrenergic receptor agonist and a compound that provides an opposite charge to a charge on the α 2 -adrenergic receptor agonist, wherein the complex is charge neutral as a whole and has a solubility in a range from about 0.3 μg/ml to about 2.5 mg/ml in water at pH of about 7 and temperature of about 25° C. The complex is included in a composition, device, or implant for use in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a composition, device, or implant can be used to provide neuroprotection to cells and components of the optic nerve system or to inhibit progression of damage to the optic nerve system resulting from glaucoma.
• BIOERODIBLE OCULAR DRUG DELIVERY INSERT AND THERAPEUTIC METHOD
  申请人：EyePoint Pharmaceuticals, Inc.

  公开号：US20220168142A1

  公开（公告）日：2022-06-02

  This invention relates to implantable bioerodible inserts for delivering an active pharmaceutical ingredient to the eye. The invention also relates to methods of treatment using such inserts as well as methods of manufacturing such inserts.
• US8034813B2
  申请人：——

  公开号：US8034813B2

  公开（公告）日：2011-10-11
• US8420648B2
  申请人：——

  公开号：US8420648B2

  公开（公告）日：2013-04-16